(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/210538 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 5/50* (2006.01)
A61P 5/48 (2006.01)

(21) International Application Number:
PCT/IB2025/053467

(22) International Filing Date:
02 April 2025 (02.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/573,012 02 April 2024 (02.04.2024) US
63/652,620 28 May 2024 (28.05.2024) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.** [US/GB]; P.O. Box 173, Kingston Chambers, Road Town, Tortola, VG1110 (VG).

(72) Inventors: **INGALE, Sampat**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **VIDAL, Christian M.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **LINHARES, Brian M.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **SPLIID, Charlotte Bredo**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **ESTRELLA, Ana M.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **DEL CARMEN, Silvina**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **RASILE, Brett**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **CAR, Bruce D.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: BIFUNCTIONAL DEGRADERS

(57) Abstract: A composition of matter including a binding moiety, a cellular receptor-binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting the binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing in a patient or subject.

WO 2025/210538 A1